Compare GSK plc (GSK) vs Valero Energy Corporation (VLO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Valero Energy Corporation — how do they compare? GSK plc trades at $46.63 (market cap $91.88B), while Valero Energy Corporation trades at $443.84 (market cap $127.78B). The key difference: Valero Energy Corporation is the larger of the two by market cap, and GSK plc pays the higher dividend (3.9%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Valero Energy Corporation for 56 Days on average.
| GSK | VLO | |
|---|---|---|
Market Cap | $91.88B | $127.78B |
Volume | 7,730,529 | 2,570,225 |
Sector | Health | Energy |
52-Week High | $61.18 | $443.80 |
52-Week Low | $43.24 | $156.39 |
Typical Hold Time | 93 Days | 56 Days |
Enterprise Value | $111.88B | $131.26B |
Dividend Yield | 3.9% | 1.08% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $46.45, down 1.21% with bearish technical signals. The company shows strong fundamentals with revenue growth to $32.67B in 2025 and consistent earnings beats. Valuation metrics appear reasonable with P/E of 14.89 and EV/EBITDA of 8.75. Recent developments include strategic oncology partnerships and a $750M cancer therapy acquisition, positioning for long-term growth despite near-term technical weakness.
GSK presents a mixed outlook with strong profitability and pipeline expansion offset by technical bearishness and HIV patent concerns. The company's 29.73% ROE and recent earnings outperformance support investment appeal, while the bearish moving average signal and competitive pressures warrant caution. Analyst consensus leans hold with 55% neutral rating, suggesting balanced risk-reward for long-term investors.
Valero Energy (VLO) trades at $441.93, up 4.2% today, near its 52-week high with strong bullish momentum from moving averages. The stock has consistently beaten earnings estimates in recent quarters, with Q3 2026 expected at $20.17 EPS. Revenue declined to $122.69B in 2025, but net income margin improved to 5.17%, supported by a robust ROE of 29.31%. Analyst consensus is bullish with a $408.10 price target, though RSI levels indicate overbought conditions.
VLO's outlook is positive due to refining margin strength and earnings beats, but risks include volatile energy prices and potential policy impacts like diesel export bans. The stock offers growth potential with a reasonable P/E of 18.51, yet high valuation multiples and technical overbought signals warrant caution for near-term entries.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Valero Energy Corporation
Valero Energy is one of the largest independent refiners in the United States. It operates 14 refineries with a total throughput capacity of 3.2 million barrels a day in the United States, Canada, and the United Kingdom. Valero also owns 14 ethanol plants with capacity of 1.7 billion gallons of ethanol a year and holds a 50% stake in Diamond Green Diesel, which has capacity to produce 700 million gallons per year of renewable diesel.
Read more on VLO →
